Clinical trial · Observational
A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor
Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Norwegian prospective registration, observational study of patients with advanced renal cell cancer on Afinitor treatment after failure of one Tyrosine Kinase Inhibitor (TKI) ( e.g. sunitinib or sorafenib). The goal is to document the treatment algorithm of these patients in Norway and the efficacy and tolerability of Afinitor® in a pure 2.line setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Renal Cell Carcinoma (mRCC) | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| everolimis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Afinitor
- description
- Afinitor
- interventionNames
- Other: everolimis
Primary outcomes (1)
- measure
- Time to progression (TTP)
- timeFrame
- maximum of 12 months after inclusion of the last patient
Secondary outcomes (3)
- measure
- Treatment algorithm
- timeFrame
- at end of study
- description
- Follow up documentation
- measure
- Quality of life (QoL)(EORTC-QLQ C30)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Confirmed diagnosis of advanced renal cell cancer * Progression on or after one VEGF -TKI (e.g. sunitibin, sorafenib) * Written informed consent Exclusion Criteria: None Other protocol-defined inclusion/exclusion criteria may apply
References
Publications (0)
Data not yet available